ライフサイエンスコーパス: therapeutics

1 h the intent to rapidly develop vaccines and therapeutics.

2 used to optimize inflammatory bowel disease therapeutics.

3 a key step toward generating more effective therapeutics.

4 ions associated with traditional diagnostics/therapeutics.

5 s would be a breakthrough in diagnostics and therapeutics.

6 development of Sirt6 activators as tools and therapeutics.

7 ities for advances in cancer diagnostics and therapeutics.

8 segment relies on intravitreal injections of therapeutics.

9 that oxidizes more than 60% of administered therapeutics.

10 les for stem cell differentiation and cancer therapeutics.

11 in cell signaling, medical diagnostics, and therapeutics.

12 ral control, and the potential generation of therapeutics.

13 nformation for future biomechanical-mediated therapeutics.

14 zyme that is an active target for anticancer therapeutics.

15 erlying disease mechanisms and to developing therapeutics.

16 en developing clinically relevant bispecific therapeutics.

17 ght allow patient selection for novel type 2 therapeutics.

18 us potential targets for the design of novel therapeutics.

19 lenge for the effective use of EGFR-directed therapeutics.

20 ise in basic research and gene editing-based therapeutics.

21 get for further research on seizure disorder therapeutics.

22 r applicability of PSMA-targeted imaging and therapeutics.

23 amenable to antibody-based or small molecule therapeutics.

24 tial for development as cocaine use disorder therapeutics.

25 to evaluate the efficacy of many of the new therapeutics.

26 e cell death, and hence could serve as novel therapeutics.

27 Hence there is an urgent need for novel therapeutics.

28 ions for the development of novel anticancer therapeutics.

29 has a broad impact in cancer epigenetics and therapeutics.

30 the development of protein-based anticancer therapeutics.

31 ting the IRDS produced in response to cancer therapeutics.

32 ping biomarker, early intervention and novel therapeutics.

33 elucidate diabetic pathogenesis and evaluate therapeutics.

34 for catalysis, which could be exploited for therapeutics.

35 f inflammation, and evaluate the response to therapeutics.

36 towards the development of disease-modifying therapeutics.

37 ocial threats, providing a viable target for therapeutics.

38 imaging agents and promising candidates for therapeutics.

39 avenues for selective and prolonged cardiac therapeutics.

40 on or as leads for the development of future therapeutics.

41 led the modern generation of targeted cancer therapeutics.

42 t TAAR1 as a novel target for wake-promoting therapeutics.

43 health monitors and advanced, bioelectronic therapeutics.

44 to evaluate the penetration and efficacy of therapeutics.

45 management could benefit from novel targeted therapeutics.

46 e processes for the development of effective therapeutics.

47 ghts into the development of RXRalpha cancer therapeutics.

48 facilitate the development of more effective therapeutics.

49 logy of diseases, and translation toward new therapeutics.

50 apatient target lesions treated with topical therapeutics.

51 nction that can be used for developing novel therapeutics.

52 triguing target for the development of novel therapeutics.

53 itate the localized and sustained release of therapeutics.

54 efficacy of cytokines and growth factors as therapeutics.

55 g target for the development of novel cancer therapeutics.

56 translating CRISPR-Cas9 nucleases into human therapeutics.

57 can serve as a powerful new class of cancer therapeutics.

58 levels in patients and the design of future therapeutics.

59 tic pathways, which is key for the future of therapeutics.

60 ial nature and lack of effective diagnostics/therapeutics.

61 d target for antibody and nanoparticle based therapeutics.

62 critically important in the discovery of new therapeutics.

63 any of the current limitations in cell-based therapeutics.

64 e pathogenesis and the development of dengue therapeutics.

65 the controlled encapsulation and release of therapeutics.

66 mplications for the development of TCR-based therapeutics.

67 biology and informed the development of new therapeutics.

68 CARD9 illustrate a path toward improved IBD therapeutics.

69 hophysiology and for developing experimental therapeutics.

70 adhesivity and receptor targeting as 'DART' therapeutics.

71 f the organisms under investigation as novel therapeutics.

72 nervous system, cardiovascular and oncology therapeutics.

73 es new targets for the development of cancer therapeutics.

74 timately increasing patient access to living therapeutics.

75 evelop innovative engineered stem cell-based therapeutics.

76 portant challenges faced by current anti-AXL therapeutics.

77 soform specific HDAC inhibitors as effective therapeutics.

78 paid to small organic molecules and protein therapeutics.

79 the promise for the development of selective therapeutics.

80 old for the development of new TLR4-directed therapeutics.

81 new opportunities to impact diagnostics and therapeutics.

82 be a potential mechanism for developing SLE therapeutics.

83 ition of GtfBCD would provide anti-virulence therapeutics.

84 ion proteinopathies and advancing anti-prion therapeutics.

85 hysiologic understanding and fostering novel therapeutics.

86 action inhibitors as a novel class of cancer therapeutics.

87 ound for the development of novel anticancer therapeutics.

88 robust platform to produce highly functional therapeutics.

89 e important clinical consequences, including therapeutics.

90 rve as hotspots for the development of novel therapeutics.

91 hanisms and promote the development of novel therapeutics.

92 hanistic probes, chemical biology tools, and therapeutics.

93 an essential obstacle to brain transport of therapeutics.

94 multiple myeloma, with several FDA-approved therapeutics.

95 rrhythmias, and discusses K(+) channel-based therapeutics.

96 rategy for the delivery of biomacromolecular therapeutics.

97 r biological processes, and discovery of new therapeutics.

98 and is an established target for anticancer therapeutics.

99 design, and subsequent development of novel therapeutics.

100 screens for anti-protofibril diagnostics and therapeutics.

101 d deployment of host- and/or fungal-targeted therapeutics.

102 f dengue pathogenesis and the development of therapeutics.

103 protein function, and to precisely engineer therapeutics.

104 lenge model and may be developed into future therapeutics.

105 point for the discovery of new antimelanoma therapeutics.

106 001 through 2010, the FDA approved 222 novel therapeutics (183 pharmaceuticals and 39 biologics).

107 ystemic and intra-arterial administration of therapeutics ( 3 - 5 ).

108 Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study profiled patients with mild,

109 2.5-6.0 years), and the proportion of novel therapeutics affected by a postmarket safety event at 10

110 pathology, implicating statins as potential therapeutics against a subset of pulmonary LCH.

111 retase is an important target for developing therapeutics against Alzheimer's disease.

112 s, which holds promise for developing common therapeutics against both threats.

113 and development of vaccines, diagnostics and therapeutics against influenza virus by providing a comp

114 and guides the development of broad-spectrum therapeutics against influenza virus.

115 site interaction can be exploited to develop therapeutics against P. vivax malaria.

116 Natural products have served as powerful therapeutics against pathogenic bacteria since the golde

117 ing evaluated for testing novel vaccines and therapeutics against pneumonic tularemia.

118 roviding a useful tool in the search for new therapeutics against this challenging disease target.

119 Targeted cancer therapeutics aim to exploit tumor-specific, genetic vuln

120 ce for its application in the development of therapeutics aimed at correcting the conformation of pol

121 ay have broad translational implications for therapeutics aimed at improving islet function.

122 of the same substrate may aid in developing therapeutics aimed at reducing PRMT5/7 activity in cance

123 Thus, drugs and therapeutics already in development for targeting these

124 They are also being developed as oncolytic therapeutics and as gene therapy vectors.

125 linical results based on the use of targeted therapeutics and biomarker-guided clinical trials, are f

126 cific subtypes of this disease using current therapeutics and by identifying targets for new groups.

127 pathological disease progression/response to therapeutics and change in clinical state.

128 disease pathogenesis and the development of therapeutics and diagnostics for Huntington's disease.

129 h of gold nanoparticle applications in laser therapeutics and diagnostics has brought about the need

130 determine a treatment strategy by combining therapeutics and diagnostics in the same agent.

131 Theranostics, a modern approach combining therapeutics and diagnostics, is among the most promisin

132 -mediated responses, including anti-cytokine therapeutics and dietary therapy.

133 al for designing and screening novel protein therapeutics and for understanding their pharmacokinetic

134 rophages can strengthen the effectiveness of therapeutics and improve clinical outcomes.

135 rged as the most promising of the cell-cycle therapeutics and intense efforts are now underway to exp

136 opment of next-generation RNAi pathway-based therapeutics and promises to accelerate our search for n

137 riant proteins to create a blueprint for IBD therapeutics and recapitulated the mechanism of the CARD

138 lvage pathway as potential targets for novel therapeutics and suggests a previously undefined role fo

139 Thus, therapeutics and vaccines restricting production of afuc

140 viral infections informs the development of therapeutics and vaccines.

141 ncy will facilitate the development of novel therapeutics and vaccines.

142 ork, including the first clinical trials for therapeutics and vaccines.

143 tform with broad applicability for research, therapeutics, and biotechnology.

144 tial for developing more-effective vaccines, therapeutics, and surveillance capabilities.

145 themselves to patient-specific diagnostics, therapeutics, and tissue regeneration.

146 ency of postmarket safety events among novel therapeutics approved by the US Food and Drug Administra

147 Therapeutics are currently unavailable for Venezuelan eq

148 Nucleic acid therapeutics are limited by inefficient delivery to targ

149 However, cell targeted therapeutics are limited by their complexity, heterogene

150 Effective cell-targeted therapeutics are needed, but the cellular origin of BMF

151 accines do not exist and effective antiviral therapeutics are needed.

152 Novel therapeutics are required for improving the management o

153 These safety events can change how novel therapeutics are used in clinical practice and inform pa

154 Many proteins, especially those used as therapeutics, are unstable to storage and shipping tempe

155 of combinational therapy using nucleic acid therapeutics, articulating the main challenges to advanc

156 itopes could greatly accelerate discovery of therapeutics as compared to conventional immunization or

157 d tremendous attention for delivering cancer therapeutics as they provide benefits including controll

158 disease and are prominent targets for novel therapeutics as well as for biomarkers for diagnostic in

159 ulator (CFTR) is key for the optimization of therapeutics as well as obtaining insights into the mole

160 unction and have potential as nervous system therapeutics as well.

161 of Retina Specialists Research and Safety in Therapeutics (ASRS ReST) Committee, an independent task

162 ese data raise the possibility of developing therapeutics based on microbiota-derived indole or its d

163 s persist in antisense oligonucleotide (ASO) therapeutics because it has been feasible neither to sep

164 ctors and high throughput screening of novel therapeutics becoming the mainstay of treatment.

165 m to solve for widespread development of RNA therapeutics, but recent chemistry advances have begun t

166 and utilization, providing the potential for therapeutics by manipulating nuclear regulation of mitoc

167 mune responses to experimental protein-based therapeutics can arise.

168 arkers are imperative before any preclinical therapeutics can find clinical translation.

169 n studies and rapid screening of cancer drug therapeutics/carriers.

170 e Airway Disease Endotyping for Personalized Therapeutics cohort.

171 Most satiety-inducing obesity therapeutics, despite modest efficacy, have safety conce

172 SMA therapeutics development efforts have focused on identif

173 e as foundation for the development of novel therapeutics, diagnostics, and vaccine candidates to com

174 hat are likely to be used as novel microbial therapeutics, discuss the regulatory framework required,

175 that it could be used for all Fc containing therapeutics (e.g. antibodies, bispecific antibodies, an

176 which are currently refractory to available therapeutics (e.g., hypertension).

177 e) seems to have potential to make AKT-based therapeutics effective clinically.

178 egivers, investigational site personnel, PTC Therapeutics employees, and all other study personnel we

179 tinues to hamper the effectiveness of cancer therapeutics engineered to destroy solid tumors using di

180 perspectives of delivery of immunomodulatory therapeutics, engineering immune cells, and constructing

181 inhibitors have emerged as promising cancer therapeutics especially for tumors with deficient homolo

182 facilitate the development of macromolecular therapeutics for a variety of disease indications.

183 ld facilitate improvement of diagnostics and therapeutics for affected patients with bleeding disorde

184 maceuticals tuning the neuroimmune system as therapeutics for alcohol dependence.

185 A major setback in improving current therapeutics for autoimmunity is the lack of antigen spe

186 ands have commonly been targeted by antibody therapeutics for cancers and other diseases.

187 lation of MCs may be important in developing therapeutics for cholangiopathies.

188 Mesenchymal stem cells (MSC) are promising therapeutics for critical limb ischemia (CLI).

189 or the stratification and development of new therapeutics for depression, and the next steps that nee

190 tion and facilitate the development of novel therapeutics for FLCN-deficient kidney cancer.

191 ion that may be exploited for development of therapeutics for FSHD.

192 emicals have gained attention as alternative therapeutics for managing cardiovascular diseases.

193 lyase inhibitors may also serve as potential therapeutics for metabolic disease; rather than disrupt

194 acilitate the development of next generation therapeutics for MPS.

195 mbination cancer therapy using nucleic acids therapeutics for successful clinical translation.

196 forms have shown promise as a novel class of therapeutics for the precision treatment of cancer.

197 ica, there are still no approved vaccines or therapeutics for the treatment of acute EBOV disease (EV

198 There are no approved therapeutics for the treatment of dengue disease despite

199 nd introduce NMDA-R antagonists as potential therapeutics for this fatal disease.

200 progress in preclinical research on cellular therapeutics for traumatic injury and its sequelae and d

201 s of vascular remodeling and have promise as therapeutics for vascularization applications.

202 Thus, ROCK inhibitors represent potential therapeutics for VHL-deficient CC-RCC.

203 ling, whereas radiomitigating TLR-activating therapeutics given after exposure are less defined.

204 Although an array of new therapeutics has emerged for the treatment of colorectal

205 Plasmodium falciparum resistant to frontline therapeutics has prompted efforts to identify and valida

206 Attempts to develop anti-prion therapeutics have been impeded by the lack of screening

207 MODS is entirely supportive, and no specific therapeutics have been shown to be effective in reducing

208 As therapeutics have evolved and multiplied in number, the

209 Clinical studies with broad and targeted therapeutics have helped to elucidate the contribution o

210 ch as cyclosporine are among the most potent therapeutics identified to date, but there is currently

211 ancer and inflammation management, including therapeutics, imaging and theranostics.

212 othelial disorders and screen their possible therapeutics in a mechanistic and high-throughput manner

213 kers and molecular targets for developmental therapeutics in aggressive PCa.

214 sclerosis and the potential for proresolving therapeutics in atherosclerosis.

215 barrier and drive widespread distribution of therapeutics in brain parenchyma away from the point of

216 hways and the current state of CSC-targeting therapeutics in combinatory treatments in clinical trial

217 iate potential for serving as biomarkers and therapeutics in dermatology over the next decade.

218 t regulation is a promising target for novel therapeutics in heart disease.

219 n provide insight to inform antihypertensive therapeutics in individuals with variants having reduced

220 relating to pharmacology, has left integrin therapeutics in need of a new strategy.

221 otential positive indicator for MET-targeted therapeutics in NSCLC.

222 d deserves further development for potential therapeutics in osteoporosis.

223 The poor efficacy of systemic cancer therapeutics in pancreatic ductal adenocarcinoma (PDAC)

224 raged in the development of species-specific therapeutics in the effort to combat multidrug resistanc

225 es in determining safety and efficacy of new therapeutics in the future.

226 el may serve as a platform to test candidate therapeutics in this aggressive subset of AML.

227 lishing the models used for testing anti-tau therapeutics in vivo.

228 vel tool for the delivery of a wide-range of therapeutics independent of formulation, potentially all

229 of nanocarriers for the targeted delivery of therapeutics into aberrant cells that overexpress the LD

230 lth concern, and the development of curative therapeutics is urgently needed.

231 he activity of the "drug-free macromolecular therapeutics" is based on the biorecognition of compleme

232 on, a process commonly targeted by antiviral therapeutics, is not well understood.

233 Towards development of EVs as therapeutics, it has been demonstrated that physiologica

234 identified 24 antibodies or antibody-related therapeutics labeled with PET radionuclides for theranos

235 Similarly, nucleoside-based therapeutics may adopt different conformations affecting

236 eristics, and the effectiveness of MSC-based therapeutics may be realized by finding predictive featu

237 Biguanides, such as the diabetes therapeutics metformin and phenformin, have shown antitu

238 response to treatments and novel preventive therapeutics need to be discovered, employed and widely

239 gies that can be quickly deployed to develop therapeutics needed to contain the outbreak.

240 EVs take part in the response to anticancer therapeutics not least by promoting drug resistance thro

241 tamatergic system to the pathophysiology and therapeutics of mood disorders.

242 urther studies of the pathogenic process and therapeutics of PD.

243 Antibody therapeutics offer effective treatment options for a bro

244 llenge for the development of macromolecular therapeutics or diagnostics.

245 of senescence and target of anti-senescence therapeutics, or senolytics.

246 ermeability, transdermal delivery of protein therapeutics poses a significant challenge.

247 automated reprogramming actions for directed therapeutics.Protein-based biosensors have been engineer

248 ill provide a brief account of the status of therapeutics research and development for dengue.

249 ne marrow niche can be altered by anticancer therapeutics, resulting in drug resistance through cell-

250 and intracellular signaling pathway-targeted therapeutics, reviewed herein.

251 ements in basic research, biotechnology, and therapeutics science that these developments have facili

252 Antisense oligonucleotide (ASO) therapeutics show tremendous promise for the treatment o

253 ideally suit the requirements of cell-based therapeutics, since they permit to characterize cells wi

254 Thus, we also review therapeutics strategies being utilized or developed to l

255 in the circulation limits the application of therapeutics such as single-domain antibodies (VHHs).

256 tive rechallenge rates with other innovative therapeutics suggest that caution should be taken with r

257 Current HCMV therapeutics target lytic replication, but not the laten

258 eg cell behavior and affects the efficacy of therapeutics targeting cancer checkpoints.

259 y and been accompanied by the development of therapeutics targeting mutant oncogenes.

260 traditionally been successfully treated with therapeutics targeting the IL-1 pathway; however, there

261 aid the discovery process for development of therapeutics targeting the mitochondrial machinery.

262 or the development of specific and effective therapeutics targeting this nontranslational function.

263 arting point for the development of diabetes therapeutics that are devoid of the blood pressure effec

264 e developed a new paradigm in macromolecular therapeutics that avoids the use of low molecular weight

265 Hence, novel therapeutics that can rebalance the ratio of regulatory

266 for the development of viable antivirulence therapeutics that combat cholera and, potentially, other

267 ify gene expression signatures and candidate therapeutics that could improve the treatment of metasta

268 global effort to develop a new generation of therapeutics that inhibit the interaction of CGRP with i

269 ed, and epidemiology studies have championed therapeutics that mitigate these adverse outcomes.

270 cations could be mitigated by developing new therapeutics that safely neutralize anticoagulant activi

271 thoroughly discuss the development of novel therapeutics that simultaneously target TAMs and tumor h

272 As such, investigation of therapeutics that target dysregulated pathways or proces

273 Novel antimalarial therapeutics that target multiple stages of the parasite

274 s of Flunarizine are low and specific sepsis therapeutics that target the dysregulated host response

275 With no available vaccines or therapeutics, the study of MERS-CoV pathogenesis is cruc

276 suggesting a novel route to immunomodulatory therapeutics.The cytokine interleukin 1alpha (IL-1alpha)

277 tly needed to guide the development of novel therapeutics: These would be designed to reverse lymphat

278 kers are needed to assess the ability of HBV therapeutics to achieve functional and virologic cure in

279 melanocortin receptor family is a target for therapeutics to ameliorate metabolic dysfunction.

280 y Bayesian decision analysis (BDA) to cancer therapeutics to choose an alpha and sample size that min

281 mising scaffold for the development of novel therapeutics to increase TIMP-3 levels and inhibit carti

282 We evaluate the major challenges in choosing therapeutics to prevent congenital ZIKV disease and cond

283 Progress in research and developing therapeutics to prevent diabetic kidney disease (DKD) is

284 To develop novel therapeutics to target YBX1, it is of great importance t

285 of NaV1.7 have the potential to yield novel therapeutics to treat pain.

286 viors and could be a novel target to develop therapeutics to treat psychiatric disorders.

287 We also describe how therapeutics used for psychiatric disorders act on the p

288 Proteins are important biologic therapeutics used for the treatment of various diseases.

289 Erythropoietin (EPO) is one of the main therapeutics used to treat anemic patients, greatly impr

290 esearch requires pre-clinical testing of new therapeutics using both in-vitro and in-vivo models.

291 ctures for the development of small-molecule therapeutics, very little is known about the environment

292 ext of treatment trials to improve and guide therapeutics via advanced neurobiological understanding

293 virulence determinants or the evaluation of therapeutics, we infected them with a green fluorescent

294 To facilitate development of topical therapeutics, we need an efficient model for assessing d

295 involvement in carcinogenesis and to develop therapeutics, which we review here.

296 eens will enable the identification of novel therapeutics whose discovery has otherwise been hindered

297 es wireless locomotion and on-site triggered therapeutics with a single external power source (i.e.,

298 This may result in highly differentiated therapeutics with greater efficacy and/or improved safet

299 very could provide a strategy to concentrate therapeutics within a unique, cardiac-restricted compart

300 odegradable nanoparticle carrier to localize therapeutics within the tissue, and ii) a novel tandem p